ReviewOphthalmic research2026
Ocular Manifestations and Management of Graft-versus-Host Disease: A Comprehensive Review.
Review in Ophthalmic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOcular graft-versus-host disease (oGVHD) is a critical complication following allogeneic haematopoietic stem cell transplantation, characterised by a T-cell-mediated immune response that results in inflammation and damage to various ocular structures. SUMMARY: While the ocular surface is primarily affected, oGVHD can also impact other eye components, leading to debilitating symptoms. The diagnosis of oGVHD poses significant challenges due to its relapsing and remitting nature, complicating effective treatment strategies. Prompt identification of ocular manifestations is essential, as early intervention can prevent vision-threatening complications and improve patient outcomes. As research continues to evolve, understanding the underlying mechanisms and exploring innovative therapeutic options will be crucial in managing this complex condition effectively. KEY MESSAGE: This review highlights the importance of heightened awareness among healthcare providers regarding the ocular signs of GVHD, advocating for timely diagnosis and personalised treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.